Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Expert Review of Anticancer Therapy|April 18, 2020
EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapyPauline Hulo, Dahna Coupez, Marc G Denis, et al.Expert Opinion on Biological Therapy|January 19, 2020
Pembrolizumab for the treatment of colorectal cancerDahna Coupez, Pauline Hulo, Yann Touchefeu, et al.Expert Opinion on Biological Therapy|August 11, 2021
KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicineDahna Coupez, Pauline Hulo, Yann Touchefeu, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 11, 2023
Overview of premedication prescription and intake in an oncology day hospital: What do we need to change to improve patient management?Annabel Goubil, Laurine Lallier, Elodie Peyrilles, et al.Gynecologic Oncology|December 15, 2022
Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinomaEmeline Colomba, Jérôme Alexandre, Gwénaël Le Teuff, et al.Clinics and Research in Hepatology and Gastroenterology|February 21, 2022
MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancerEmeric Boisteau, Alexandra Lespagnol, Marie De Tayrac, et al.Clinical Lung Cancer|July 2, 2020
Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer PatientsElisa Gobbini, Anne Claire Toffart, Maurice Pérol, et al.Pageof 1